HRP20121021T1 - SPOJ 3-FENILPIRAZOLO[5,1-b]TIAZOLA - Google Patents
SPOJ 3-FENILPIRAZOLO[5,1-b]TIAZOLA Download PDFInfo
- Publication number
- HRP20121021T1 HRP20121021T1 HRP20121021AT HRP20121021T HRP20121021T1 HR P20121021 T1 HRP20121021 T1 HR P20121021T1 HR P20121021A T HRP20121021A T HR P20121021AT HR P20121021 T HRP20121021 T HR P20121021T HR P20121021 T1 HRP20121021 T1 HR P20121021T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- compound according
- methoxy
- salt
- thiazol
- Prior art date
Links
- -1 3-PHENYLPYRAZOLO[5,1-b]THIAZOLE COMPOUND Chemical class 0.000 title claims 10
- 150000001875 compounds Chemical class 0.000 claims 28
- 150000003839 salts Chemical class 0.000 claims 11
- 208000019901 Anxiety disease Diseases 0.000 claims 4
- 230000036506 anxiety Effects 0.000 claims 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000000069 prophylactic effect Effects 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 206010008190 Cerebrovascular accident Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000033463 Ischaemic neuropathy Diseases 0.000 claims 2
- 206010054048 Postoperative ileus Diseases 0.000 claims 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000022531 anorexia Diseases 0.000 claims 2
- 230000036461 convulsion Effects 0.000 claims 2
- 206010061428 decreased appetite Diseases 0.000 claims 2
- 230000001079 digestive effect Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 206010013663 drug dependence Diseases 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 231100000318 excitotoxic Toxicity 0.000 claims 2
- 230000003492 excitotoxic effect Effects 0.000 claims 2
- 206010022437 insomnia Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- IFYKMCAPVKAGQX-UHFFFAOYSA-N 3-[2,6-dimethoxy-4-(methoxymethyl)phenyl]-6-methoxy-n-(oxan-4-yl)-n-propylpyrazolo[5,1-b][1,3]thiazol-7-amine Chemical compound COC1=NN2C(C=3C(=CC(COC)=CC=3OC)OC)=CSC2=C1N(CCC)C1CCOCC1 IFYKMCAPVKAGQX-UHFFFAOYSA-N 0.000 claims 1
- ZOEBQJWEMYNPDT-UHFFFAOYSA-N 3-[2-chloro-6-methoxy-4-(methoxymethyl)phenyl]-6-methoxy-n-(oxan-4-yl)-n-propylpyrazolo[5,1-b][1,3]thiazol-7-amine Chemical compound COC1=NN2C(C=3C(=CC(COC)=CC=3Cl)OC)=CSC2=C1N(CCC)C1CCOCC1 ZOEBQJWEMYNPDT-UHFFFAOYSA-N 0.000 claims 1
- REEHHYCKBNOQNI-UHFFFAOYSA-N 3-[4-(ethoxymethyl)-2,6-dimethoxyphenyl]-6-methoxy-n-(oxan-3-yl)-n-propylpyrazolo[5,1-b][1,3]thiazol-7-amine Chemical compound COC1=NN2C(C=3C(=CC(COCC)=CC=3OC)OC)=CSC2=C1N(CCC)C1CCCOC1 REEHHYCKBNOQNI-UHFFFAOYSA-N 0.000 claims 1
- JLSWTZVCHXNYGF-UHFFFAOYSA-N 4-[7-[cyclopropylmethyl(oxolan-3-ylmethyl)amino]-6-methoxypyrazolo[5,1-b][1,3]thiazol-3-yl]-3,5-dimethoxybenzonitrile Chemical compound COC1=NN2C(C=3C(=CC(=CC=3OC)C#N)OC)=CSC2=C1N(CC1COCC1)CC1CC1 JLSWTZVCHXNYGF-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 206010054089 Depressive symptom Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000029650 alcohol withdrawal Diseases 0.000 claims 1
- 229910052801 chlorine Chemical group 0.000 claims 1
- 239000000460 chlorine Chemical group 0.000 claims 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- CIEVCSWHRZMADV-UHFFFAOYSA-N n-(2-cyclopropylethyl)-3-[4-(ethoxymethyl)-2,6-dimethoxyphenyl]-6-methoxy-n-(oxan-4-yl)pyrazolo[5,1-b][1,3]thiazol-7-amine Chemical compound COC1=CC(COCC)=CC(OC)=C1C(N1N=C2OC)=CSC1=C2N(C1CCOCC1)CCC1CC1 CIEVCSWHRZMADV-UHFFFAOYSA-N 0.000 claims 1
- DVZMOOXPINUDLM-UHFFFAOYSA-N n-(cyclobutylmethyl)-3-[2,6-dimethoxy-4-(methoxymethyl)phenyl]-6-methoxy-n-(oxan-4-yl)pyrazolo[5,1-b][1,3]thiazol-7-amine Chemical compound COC1=CC(COC)=CC(OC)=C1C(N1N=C2OC)=CSC1=C2N(C1CCOCC1)CC1CCC1 DVZMOOXPINUDLM-UHFFFAOYSA-N 0.000 claims 1
- NFOXKSLQJXDWGK-UHFFFAOYSA-N n-(cyclopropylmethyl)-3-[2,6-dimethoxy-4-(methoxymethyl)phenyl]-6-methoxy-n-(oxan-4-yl)pyrazolo[5,1-b][1,3]thiazol-7-amine Chemical compound COC1=CC(COC)=CC(OC)=C1C(N1N=C2OC)=CSC1=C2N(C1CCOCC1)CC1CC1 NFOXKSLQJXDWGK-UHFFFAOYSA-N 0.000 claims 1
- SZHOIIKHFGGEKW-UHFFFAOYSA-N n-(cyclopropylmethyl)-6-methoxy-n-(oxan-4-ylmethyl)-3-(2,4,6-trimethoxyphenyl)pyrazolo[5,1-b][1,3]thiazol-7-amine Chemical compound COC1=NN2C(C=3C(=CC(OC)=CC=3OC)OC)=CSC2=C1N(CC1CCOCC1)CC1CC1 SZHOIIKHFGGEKW-UHFFFAOYSA-N 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- COWJNZFMPUADKV-UHFFFAOYSA-N n-butyl-3-[2,6-dimethoxy-4-(methoxymethyl)phenyl]-6-methoxy-n-(oxan-4-yl)pyrazolo[5,1-b][1,3]thiazol-7-amine Chemical compound COC1=NN2C(C=3C(=CC(COC)=CC=3OC)OC)=CSC2=C1N(CCCC)C1CCOCC1 COWJNZFMPUADKV-UHFFFAOYSA-N 0.000 claims 1
- MKMSLJYQGXJIQH-UHFFFAOYSA-N n-butyl-3-[4-(ethoxymethyl)-2,6-dimethoxyphenyl]-6-methoxy-n-(oxan-4-yl)pyrazolo[5,1-b][1,3]thiazol-7-amine Chemical compound COC1=NN2C(C=3C(=CC(COCC)=CC=3OC)OC)=CSC2=C1N(CCCC)C1CCOCC1 MKMSLJYQGXJIQH-UHFFFAOYSA-N 0.000 claims 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 125000006173 tetrahydropyranylmethyl group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (18)
1. Spoj prikazan sa formulom (I) ili njegova sol:
[image]
naznačen time da
R1 predstavlja formulu -A11-A12;
R2 predstavlja tetrahidrofurilmetil, tetrahidropiranilmetil ili tetrahidropiranil; A11 predstavlja jednostruku vezu, metilen ili 1,2-etilen;
A12 predstavlja C1-6 alkil, C3-6 cikloalkil, ili C3-6 cikloalkil supstituiran sa metilnom skupinom;
R3 predstavlja metoksi, cijano, ciklobutiloksimetil, metoksimetil ili etoksimetil; i
R4 predstavlja metoksi ili klor.
2. Spoj prema zahtjevu 1, naznačen time da R2 je tetrahidropiran-4-il, tetrahidropiran-3-il, (tetrahidropiran-4-il)metil ili (tetrahidrofuran-3-il)metil.
3. Spoj prema zahtjevu 1 ili zahtjevu 2, naznačen time da R1 je n-propil, n-butil, n-pentil, ciklopropilmetil, ciklobutilmetil, 2-(ciklopropil)etil ili (2-metilciklopropil)metil.
4. Spoj prema zahtjevu 1, naznačen time da spoj je N-butil-3-[2,6-dimetoksi-4-(metoksimetil)fenil]-6-metoksi-N-(tetrahidro-2H-piran-4-il)pirazolo[5,1-b][1,3]tiazol-7-amin ili njegova sol.
5. Spoj prema zahtjevu 1, naznačen time da spoj je N-butil-3-[4-(etoksimetil)-2,6-dimetoksifenil]-6-metoksi-N-(tetrahidro-2H-piran-4-il)pirazolo[5,1-b][1,3]tiazol-7-amin ili njegova sol.
6. Spoj prema zahtjevu 1, naznačen time da spoj je N-(2-ciklopropiletil)-3-[4-(etoksimetil)-2,6-dimetoksifenil]-6-metoksi-N-(tetrahidro-2H-piran-4-il)pirazolo[5,1-b][1,3]tiazol-7-amin ili njegova sol.
7. Spoj prema zahtjevu 1, naznačen time da spoj je 3-[4-(etoksimetil)-2,6-dimetoksifenil]-6-metoksi-N-propil-N-(tetrahidro-2H-piran-3-il)pirazolo[5,1-b][1,3]tiazol-7-amin ili njegova sol.
8. Spoj prema zahtjevu 1, naznačen time da spoj je N-(ciklobutilmetil)-3-[2,6-dimetoksi-4-(metoksimetil)fenil]-6-metoksi-N-(tetrahidro-2H-piran-4-il)pirazolo[5,1-b][1,3]tiazol-7-amin ili njegova sol.
9. Spoj prema zahtjevu 1, naznačen time da spoj je N-(ciklopropilmetil)-3-[2,6-dimetoksi-4-(metoksimetil)fenil]-6-metoksi-N-(tetrahidro-2H-piran-4-il)pirazolo[5,1-b][1,3]tiazol-7-amin ili njegova sol.
10. Spoj prema zahtjevu 1, naznačen time da spoj je 3-[2,6-dimetoksi-4-(metoksimetil)fenil]-6-metoksi-N-propil-N-(tetrahidro-2H-piran-4-il)pirazolo[5,1-b][1,3]tiazol-7-amin ili njegova sol.
11. Spoj prema zahtjevu 1, naznačen time da spoj je 3-[2-chloro-6-metoksi-4-(metoksimetil)fenil]-6-metoksi-N-propil-N-(tetrahidro-2H-piran-4-il)pirazolo[5,1-b][1,3]tiazol-7-amin ili njegova sol.
12. Spoj prema zahtjevu 1, naznačen time da spoj je 4-{7-[(ciklopropilmetil)(tetrahidrofuran-3-ilmetil)amino]-6-metoksipirazolo[5,1-b][1,3]tiazol-3-il}-3,5-dimetoksibenzonitril ili njegova sol.
13. Spoj prema zahtjevu 1, naznačen time da spoj je N-(ciklopropilmetil)-6-metoksi-N-(tetrahidro-2H-piran-4-ilmetil)-3-(2,4,6-trimetoksifenil)-pirazolo[5,1-b][1,3]tiazol-7-amin ili njegova sol.
14. Farmaceutski pripravak naznačen time da sadrži spoj prema bilo kojem od zahtjeva 1-13 kao aktivni sastojak.
15. Terapeutsko ili profilaktičko sredstvo koje sadrži spoj prema bilo kojem od zahtjeva 1-13 naznačeno time da je za uporabu kod liječenja ili sprečavanja depresije, simptoma depresije, tjeskobe, sindroma iritabilnog crijeva, poremećaja spavanja, nesanice, ovisnosti o alkoholu, simptoma odvikavanja od alkohola, ovisnosti o drogama, simptoma odvikavanja od droga, probavnih poremećaja vezanih uz stres, anoreksije, poremećaja prehrane, postoperativnog ileusa, ishemijske neuropatije, apopleksije, ekscitotoksične neuropatije, konvulzija, epilepsije, hipertenzije, shizofrenije, bipolarnog poremećaja ili demencije.
16. Terapeutsko ili profilaktičko sredstvo za uporabu prema zahtjevu 15, naznačeno time da terapeutsko ili profilaktičko sredstvo je za uporabu kod liječenja ili sprečavanja depresije, simptoma depresije, tjeskobe ili sindroma iritabilnog crijeva.
17. Spoj prema bilo kojem od zahtjeva 1-13 naznačen time da je za uporabu kod liječenja ili sprečavanja depresije, simptoma depresije, tjeskobe, sindroma iritabilnog crijeva, poremećaja spavanja, nesanice, ovisnosti o alkoholu, simptoma odvikavanja od alkohola, ovisnosti o drogama, simptoma odvikavanja od droga, probavnih poremećaja vezanih uz stres, anoreksije, poremećaja prehrane, postoperativnog ileusa, ishemijske neuropatije, apopleksije, ekscitotoksične neuropatije, konvulzija, epilepsije, hipertenzije, shizofrenije, bipolarnog poremećaja ili demencije.
18. Spoj za uporabu prema zahtjevu 17, naznačen time da je spoj za uporabu kod liječenja ili sprečavanja depresije, simptoma depresije, tjeskobe ili sindroma iritabilnog crijeva.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4508408P | 2008-04-15 | 2008-04-15 | |
| JP2008106080 | 2008-04-15 | ||
| PCT/JP2009/057270 WO2009128383A1 (ja) | 2008-04-15 | 2009-04-09 | ３－フェニルピラゾロ［５，１－ｂ］チアゾール化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20121021T1 true HRP20121021T1 (hr) | 2013-01-31 |
Family
ID=41164535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20121021AT HRP20121021T1 (hr) | 2008-04-15 | 2012-12-12 | SPOJ 3-FENILPIRAZOLO[5,1-b]TIAZOLA |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US8431603B2 (hr) |
| EP (1) | EP2266990B1 (hr) |
| JP (1) | JP4654325B2 (hr) |
| KR (1) | KR101601994B1 (hr) |
| CN (1) | CN102007133B (hr) |
| AR (1) | AR071655A1 (hr) |
| AU (1) | AU2009237050B2 (hr) |
| BR (1) | BRPI0911659B8 (hr) |
| CA (1) | CA2721670C (hr) |
| CL (1) | CL2009000896A1 (hr) |
| CY (1) | CY1113484T1 (hr) |
| DK (1) | DK2266990T3 (hr) |
| ES (1) | ES2396126T3 (hr) |
| HK (2) | HK1150310A1 (hr) |
| HR (1) | HRP20121021T1 (hr) |
| IL (1) | IL208393A (hr) |
| MX (1) | MX2010011089A (hr) |
| MY (1) | MY152687A (hr) |
| NZ (1) | NZ588376A (hr) |
| PE (1) | PE20091890A1 (hr) |
| PL (1) | PL2266990T3 (hr) |
| PT (1) | PT2266990E (hr) |
| RS (1) | RS52561B (hr) |
| RU (1) | RU2482120C2 (hr) |
| SI (1) | SI2266990T1 (hr) |
| TW (1) | TW201004964A (hr) |
| UA (1) | UA101836C2 (hr) |
| WO (1) | WO2009128383A1 (hr) |
| ZA (1) | ZA201006764B (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2266990E (pt) | 2008-04-15 | 2012-12-27 | Eisai R&D Man Co Ltd | Composto de 3-fenilpirazolo[5,1-b]tiazole |
| WO2011043387A1 (ja) | 2009-10-08 | 2011-04-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾロオキサゾール化合物 |
| AR078521A1 (es) | 2009-10-08 | 2011-11-16 | Eisai R&D Man Co Ltd | Compuesto pirazolotiazol |
| CN102020587A (zh) * | 2010-11-25 | 2011-04-20 | 大连凯飞精细化工有限公司 | 2-甲氧基-4-氰基苯甲醛的合成方法 |
| TWI679205B (zh) * | 2014-09-02 | 2019-12-11 | 日商日本新藥股份有限公司 | 吡唑并噻唑化合物及醫藥 |
| CN115010621B (zh) * | 2022-07-21 | 2023-11-03 | 山东百启生物医药有限公司 | 一种4-溴-3-甲基苯甲腈的合成方法 |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US224974A (en) | 1880-02-24 | wheeler | ||
| JPS5320360B2 (hr) | 1973-05-30 | 1978-06-26 | ||
| JPS51141896A (en) * | 1975-05-31 | 1976-12-07 | Sankyo Co Ltd | Process for preparing fused ring triazoropyrimidine derivatives |
| EP0068378B1 (en) | 1981-06-26 | 1986-03-05 | Schering Corporation | Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them |
| US4596872A (en) * | 1985-06-05 | 1986-06-24 | Schering A.G. | Imidazo[1,2-a]pyridines, and process for their preparation |
| FR2594438B1 (fr) * | 1986-02-14 | 1990-01-26 | Labaz Sanofi Nv | Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant |
| US5190862A (en) * | 1987-04-01 | 1993-03-02 | Boehringer Mannheim Gmbh | Chromogenic compounds and the use thereof as enzyme substrates |
| US5179103A (en) * | 1987-06-15 | 1993-01-12 | Fujisawa Pharmaceutical Company, Ltd. | Pharmaceutically useful pyrazolopyridines |
| US4925849A (en) * | 1987-06-15 | 1990-05-15 | Fujisawa Pharmaceutical Company, Ltd. | Pharmaceutically useful pyrazolopyridines |
| FR2619818B1 (fr) * | 1987-09-01 | 1990-01-12 | Sanofi Sa | Imidazo (1,2-b) pyridazines, procede pour leur preparation et compositions pharmaceutiques les contenant |
| US5338743A (en) * | 1988-06-06 | 1994-08-16 | Fujisawa Pharmaceutical Co., Ltd. | New use of the adenosine antagonist |
| US5155114A (en) * | 1989-01-23 | 1992-10-13 | Fujisawa Pharmaceutical Company, Ltd. | Method of treatment using pyrazolopyridine compound |
| US5055479A (en) | 1988-06-16 | 1991-10-08 | Sankyo Company, Limited | Method of treating cachexia |
| US5127936A (en) * | 1988-07-19 | 1992-07-07 | E. I. Du Pont De Nemours And Company | Substituted phenyltriazolopyrimidine herbicides |
| JPH03506033A (ja) | 1988-07-19 | 1991-12-26 | イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー | 置換フエニルトリアゾロピリミジン除草剤 |
| CA1330079C (en) | 1988-10-13 | 1994-06-07 | Michihiko Tsujitani | Pyrrolo (3,2-e)pyrazolo(1,5-a)pyrimidine derivative and medicine comprising the same |
| JPH0688999B2 (ja) | 1988-10-13 | 1994-11-09 | ポーラ化成工業株式会社 | ピロロ〔３，２―ｅ〕ピラゾロ〔１，５―ａ〕ピリミジン誘導体およびこれを含有する医薬 |
| JPH085790B2 (ja) * | 1988-11-11 | 1996-01-24 | 杏林製薬株式会社 | 記憶障害改善薬 |
| GB8901423D0 (en) | 1989-01-23 | 1989-03-15 | Fujisawa Pharmaceutical Co | Pyrazolopyridine compound and processes for preparation thereof |
| EP0466725A1 (en) * | 1989-04-04 | 1992-01-22 | JEANS, Phillip Patrick | Equestrian training aid and method for using the same |
| DE3942355A1 (de) * | 1989-12-21 | 1991-06-27 | Boehringer Mannheim Gmbh | N- und o-substituierte aminophenolderivate, zwischenprodukte zu deren herstellung, deren verwendung als hydrolasesubstrate, ein entsprechendes bestimmungsverfahren und hierfuer geeignetes diagnostisches mittel |
| DE3942356A1 (de) * | 1989-12-21 | 1991-06-27 | Boehringer Mannheim Gmbh | Verwendung von 1-arylsemicarbaziden zur stabilisierung von enzymsubstraten, entsprechende verfahren und diagnostisches mittel enthaltend einen solchen stabilisator |
| DE3942357A1 (de) | 1989-12-21 | 1991-06-27 | Boehringer Mannheim Gmbh | 3-aminopyrazolo-heterocyclen, deren verwendung zur bestimmung von wasserstoffperoxid, wasserstoffperoxid-bildenden systemen, peroxidase, peroxidatisch wirksamen substanzen oder von elektronenreichen aromatischen verbindungen, entsprechende bestimmungsverfahren und hierfuer geeignete mittel |
| CA2060138A1 (en) | 1991-01-29 | 1992-07-30 | Youichi Shiokawa | New use of the adenosine antagonist |
| JP3295149B2 (ja) | 1991-12-26 | 2002-06-24 | ポーラ化成工業株式会社 | ピロロ［３，２−ｅ］ピラゾロ［１，５−ａ］ピリミジン誘導体 |
| FR2687675B1 (fr) * | 1992-01-31 | 1997-04-18 | Roussel Uclaf | Nouveaux derives bicycliques de la pyridine, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant. |
| JPH05271338A (ja) | 1992-03-27 | 1993-10-19 | Nippon Zeon Co Ltd | 二置換ジフェニルアセチレン系重合体 |
| WO1993025553A1 (en) * | 1992-06-17 | 1993-12-23 | The Upjohn Company | Pyridino-, pyrrolidino- and azepino-substituted oximes useful as anti-atherosclerosis and anti-hypercholesterolemic agents |
| US6765008B1 (en) | 1992-12-17 | 2004-07-20 | Pfizer Inc | Pyrrolopyrimidines as CRF antagonists |
| NZ256620A (en) | 1992-12-17 | 1996-05-28 | Pfizer | Pyrazole derivatives; compounds and pharmaceutical compositions containing them; intermediate compounds |
| RU2142946C1 (ru) | 1992-12-17 | 1999-12-20 | Пфайзер Инк. | Производные пиразола и фармацевтическая композиция, содержащая их |
| TW444018B (en) | 1992-12-17 | 2001-07-01 | Pfizer | Pyrazolopyrimidines |
| TW336932B (en) | 1992-12-17 | 1998-07-21 | Pfizer | Amino-substituted pyrazoles |
| FR2701708B1 (fr) | 1993-02-19 | 1995-05-19 | Sanofi Elf | Dérivés de 2-amido-4-phénylthiazoles polysubstitués, procédé de préparation, composition pharmaceutique et utilisation de ces dérivés pour la préparation d'un médicament. |
| DE4311460A1 (de) * | 1993-04-08 | 1994-10-13 | Boehringer Mannheim Gmbh | Verfahren zur kolorimetrischen Bestimmung eines Analyten mittels Benzylalkoholdehydrogenase und einem chromogenen Redoxindikator |
| WO1995010506A1 (en) | 1993-10-12 | 1995-04-20 | The Du Pont Merck Pharmaceutical Company | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
| FR2714059B1 (fr) * | 1993-12-21 | 1996-03-08 | Sanofi Elf | Dérivés amino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent. |
| DK0765327T3 (da) | 1994-06-16 | 1999-11-29 | Pfizer | Pyrazolo- og pyrrolopyridiner |
| JP3508033B2 (ja) | 1994-11-08 | 2004-03-22 | 旭電化工業株式会社 | エポキシ樹脂組成物 |
| US5955613A (en) | 1995-10-13 | 1999-09-21 | Neurogen Corporation | Certain pyrrolopyridine derivatives; novel CRF1 specific ligands |
| PT778277E (pt) | 1995-12-08 | 2003-11-28 | Pfizer | Derivados heterociclicos substituidos como antagonistas do crf |
| EP0882051B1 (en) | 1996-02-07 | 2001-11-07 | Janssen Pharmaceutica N.V. | Thiophenopyrimidines |
| CZ244598A3 (cs) | 1996-02-07 | 1998-10-14 | Janssen Pharmaceutica N.V. | Pyrazolopyrimidiny jako antagonisty CRF receptoru |
| US6664261B2 (en) * | 1996-02-07 | 2003-12-16 | Neurocrine Biosciences, Inc. | Pyrazolopyrimidines as CRF receptor antagonists |
| ZA973884B (en) | 1996-05-23 | 1998-11-06 | Du Pont Merck Pharma | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders |
| US6022978A (en) | 1996-06-11 | 2000-02-08 | Pfizer Inc. | Benzimidazole derivatives |
| BR9711970A (pt) | 1996-08-28 | 1999-08-24 | Pfizer | Derivados 6,5-substitu¡do-heterobic¡clicos |
| US20010007867A1 (en) * | 1999-12-13 | 2001-07-12 | Yuhpyng L. Chen | Substituted 6,5-hetero-bicyclic derivatives |
| JPH10218881A (ja) | 1997-02-03 | 1998-08-18 | Pola Chem Ind Inc | 新規なピロロピラゾロピリミジン誘導体 |
| EP0970082A2 (en) | 1997-02-18 | 2000-01-12 | Neurocrine Biosciences, Inc. | Biazacyclic crf antagonists |
| JPH1143434A (ja) | 1997-05-30 | 1999-02-16 | Pola Chem Ind Inc | カリウムチャンネル開口薬 |
| EP0994877A1 (en) | 1997-07-03 | 2000-04-26 | Du Pont Pharmaceuticals Company | Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders |
| AU9021598A (en) | 1997-08-22 | 1999-03-16 | Du Pont Pharmaceuticals Company | Nitrogen substituted imidazo{4,5-c}pyrazoles as corticotropin relea sing hormone antagonists |
| MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
| AU2298599A (en) | 1998-02-04 | 1999-08-23 | Nissan Chemical Industries Ltd. | Pyridine derivatives fused with azole and herbicide |
| US6365589B1 (en) | 1998-07-02 | 2002-04-02 | Bristol-Myers Squibb Pharma Company | Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists |
| US6271380B1 (en) | 1998-12-30 | 2001-08-07 | Dupont Pharmaceuticals Company | 1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands |
| WO2000059908A2 (en) | 1999-04-06 | 2000-10-12 | Du Pont Pharmaceuticals Company | Pyrazolopyrimidines as crf antagonists |
| AU4331500A (en) | 1999-04-06 | 2000-10-23 | Du Pont Pharmaceuticals Company | Pyrazolotriazines as crf antagonists |
| JP3795305B2 (ja) | 1999-07-19 | 2006-07-12 | 田辺製薬株式会社 | 医薬組成物 |
| KR100756592B1 (ko) * | 1999-10-08 | 2007-09-10 | 그뤼넨탈 게엠베하 | 비사이클릭 이미다조-3-일-아민 유도체, 이의 제조방법 및 이를 포함하는 진통제 |
| SE9903760D0 (sv) * | 1999-10-18 | 1999-10-18 | Astra Ab | New compounds |
| DE19948434A1 (de) * | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine |
| BR0014826A (pt) * | 1999-10-08 | 2002-08-27 | Gr Nenthal Gmbh | Imidazo-3-il-aminas bicìclicas, procedimento de sua preparação e medicamentos que as contêm |
| PL355019A1 (en) | 1999-10-08 | 2004-03-22 | Grunenthal Gmbh | Bicyclic imidazo-5-yl-amine derivatives |
| FR2801308B1 (fr) | 1999-11-19 | 2003-05-09 | Oreal | COMPOSITIONS DE TEINTURE DE FIBRES KERATINIQUES CONTENANT DE DES 3-AMINO PYRAZOLO-[1,(-a]-PYRIDINES, PROCEDE DE TEINTURE, NOUVELLES 3-AMINO PYRAZOLO-[1,5-a]-PYRIDINES |
| WO2001044248A1 (en) | 1999-12-17 | 2001-06-21 | Bristol-Myers Squibb Pharma Company | Imidazopyrimidinyl and imidazopyridinyl derivatives |
| HUP0301801A2 (hu) | 2000-07-14 | 2003-09-29 | Bristol-Myers Squibb Pharma Company | Imidazo[1,2-a]pirazin-származékok és az ezeket tartalmazó gyógyszerkészítmények |
| MY129000A (en) | 2000-08-31 | 2007-03-30 | Tanabe Seiyaku Co | INHIBITORS OF a4 MEDIATED CELL ADHESION |
| JP3617433B2 (ja) | 2000-09-05 | 2005-02-02 | 株式会社デンソー | 駆動回路 |
| JP2004531475A (ja) | 2001-01-26 | 2004-10-14 | ブリストル−マイヤーズ スクイブ カンパニー | コルチコトロピン放出因子阻害剤としてのイミダゾリル誘導体 |
| TWI312347B (en) * | 2001-02-08 | 2009-07-21 | Eisai R&D Man Co Ltd | Bicyclic nitrogen-containing condensed ring compounds |
| JP5291854B2 (ja) * | 2001-04-24 | 2013-09-18 | マサチューセッツ インスチテュート オブ テクノロジー | 炭素−ヘテロ原子間及び炭素−炭素間結合の銅を触媒とした形成 |
| CZ301491B6 (cs) | 2001-04-27 | 2010-03-24 | Eisai R&D Management Co., Ltd. | Pyrazolo[1,5-a]pyridiny a léciva s jejich obsahem |
| JP4631228B2 (ja) | 2001-07-31 | 2011-02-16 | 株式会社豊田自動織機 | ピストン式圧縮機における防振構造 |
| DE60214427T2 (de) | 2001-12-19 | 2007-04-26 | Flexitral Inc. | Verbesserte geruchsstoffe |
| MY140707A (en) | 2002-02-28 | 2010-01-15 | Mitsubishi Tanabe Pharma Corp | Process for preparing a phenylalanine derivative and intermediates thereof |
| AU2003220190A1 (en) | 2002-03-13 | 2003-09-29 | Pharmacia & Upjohn Company Llc | Pyrazolo(1,5-a)pyridine derivatives as neurotransmitter modulators |
| EP1518187A1 (de) | 2002-07-01 | 2005-03-30 | Ognjen Amidzic | Verfahren zur erstellung von daten, die für die beurteilung kognitiver oder sensomotorischer leistungsfähigkeiten oder leistungen von testpersonen verwendbar sind |
| JP2004053678A (ja) | 2002-07-16 | 2004-02-19 | Toyobo Co Ltd | Ｉｒアブレーション用積層体 |
| BRPI0313976B8 (pt) * | 2002-10-22 | 2021-05-25 | Eisai Co Ltd | compostos de 7-fenilpirazolopiridina e uso dos mesmos na preparação de agente terapêutico ou profilático para doenças associadas com o crf ou seus receptores |
| US7176216B2 (en) | 2002-10-22 | 2007-02-13 | Eisai Co., Ltd. | 7-phenylpyrazolopyridine compounds |
| JP2007515474A (ja) | 2003-12-22 | 2007-06-14 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | Ｃｒｆ受容体アンタゴニストおよびそれらに関連する方法 |
| JP2008503444A (ja) | 2004-02-13 | 2008-02-07 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | Ｃｒｆ受容体アンタゴニスト、その調製法、その医薬組成物およびその使用 |
| JP4832743B2 (ja) | 2004-03-29 | 2011-12-07 | ケンブリッジユニバーシティテクニカルサービスリミテッド | 化合物の合成方法および合成反応触媒 |
| JP4520215B2 (ja) | 2004-04-30 | 2010-08-04 | 日油株式会社 | 分子量が制御された置換ジフェニルアセチレン重合体の製造方法 |
| GB0519957D0 (en) * | 2005-09-30 | 2005-11-09 | Sb Pharmco Inc | Chemical compound |
| US8088779B2 (en) * | 2005-09-30 | 2012-01-03 | Smithkline Beecham (Cork) Limited | Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists |
| PT2266990E (pt) | 2008-04-15 | 2012-12-27 | Eisai R&D Man Co Ltd | Composto de 3-fenilpirazolo[5,1-b]tiazole |
| US7994203B2 (en) | 2008-08-06 | 2011-08-09 | Novartis Ag | Organic compounds |
| JP2010235929A (ja) | 2009-03-09 | 2010-10-21 | Sumitomo Chemical Co Ltd | 重合体 |
| TWI358017B (en) | 2009-12-17 | 2012-02-11 | Askey Computer Corp | Electronic device loading base |
-
2009
- 2009-04-09 PT PT97329072T patent/PT2266990E/pt unknown
- 2009-04-09 EP EP09732907A patent/EP2266990B1/en active Active
- 2009-04-09 MY MYPI20104527 patent/MY152687A/en unknown
- 2009-04-09 DK DK09732907.2T patent/DK2266990T3/da active
- 2009-04-09 MX MX2010011089A patent/MX2010011089A/es active IP Right Grant
- 2009-04-09 ES ES09732907T patent/ES2396126T3/es active Active
- 2009-04-09 CA CA2721670A patent/CA2721670C/en active Active
- 2009-04-09 JP JP2010508183A patent/JP4654325B2/ja active Active
- 2009-04-09 BR BRPI0911659A patent/BRPI0911659B8/pt active IP Right Grant
- 2009-04-09 KR KR1020107019769A patent/KR101601994B1/ko active IP Right Grant
- 2009-04-09 CN CN2009801131303A patent/CN102007133B/zh active Active
- 2009-04-09 NZ NZ588376A patent/NZ588376A/en not_active IP Right Cessation
- 2009-04-09 US US12/421,182 patent/US8431603B2/en active Active
- 2009-04-09 AU AU2009237050A patent/AU2009237050B2/en active Active
- 2009-04-09 PL PL09732907T patent/PL2266990T3/pl unknown
- 2009-04-09 WO PCT/JP2009/057270 patent/WO2009128383A1/ja active Application Filing
- 2009-04-09 RU RU2010146240/04A patent/RU2482120C2/ru active
- 2009-04-09 SI SI200930453T patent/SI2266990T1/sl unknown
- 2009-04-09 RS RS20120562A patent/RS52561B/en unknown
- 2009-04-10 TW TW098112062A patent/TW201004964A/zh unknown
- 2009-04-13 AR ARP090101280A patent/AR071655A1/es not_active Application Discontinuation
- 2009-04-13 PE PE2009000505A patent/PE20091890A1/es not_active Application Discontinuation
- 2009-04-14 CL CL2009000896A patent/CL2009000896A1/es unknown
- 2009-09-04 UA UAA201013461A patent/UA101836C2/ru unknown
-
2010
- 2010-09-21 ZA ZA2010/06764A patent/ZA201006764B/en unknown
- 2010-10-03 IL IL208393A patent/IL208393A/en active IP Right Grant
-
2011
- 2011-05-03 HK HK11104407.6A patent/HK1150310A1/xx not_active IP Right Cessation
- 2011-06-13 HK HK11105942.5A patent/HK1151797A1/xx not_active IP Right Cessation
-
2012
- 2012-12-12 HR HRP20121021AT patent/HRP20121021T1/hr unknown
- 2012-12-21 CY CY20121101254T patent/CY1113484T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20121021T1 (hr) | SPOJ 3-FENILPIRAZOLO[5,1-b]TIAZOLA | |
| HRP20140814T1 (hr) | Inhibitori jak2 i njihova uporaba za lijeäśenje mijeloproliferativnih bolesti i karcinoma | |
| HRP20210454T1 (hr) | 3-supstituirani 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-dion spojevi za liječenje i profilaksu virusne infekcije | |
| HRP20210949T1 (hr) | Spojevi i sastavi za moduliranje aktivnosti egfr mutant kinaze | |
| ES2569528T3 (es) | 4-pirazolil-N-arilpirimidin-2-aminas y 4-pirazolil-N-heteroarilpirimidin-2-aminas como inhibidores de quinasas Janus | |
| BRPI0406762A (pt) | Derivados de n-(1-benzil-2-oxo-2-(1-piperazinil)etil)-1-piperidincarb oxamida e compostos relacionados como antagonistas de cgrp, para tratamento de dores de cabeça | |
| JP2019504901A5 (hr) | ||
| HRP20140451T1 (hr) | Derivati izoksazola i njihova uporaba kao pojaäśivaäśa metabotropnih glutamatnih receptora | |
| HRP20120558T1 (hr) | Kapa-selektivni antagonist opioidnih receptora | |
| HRP20160647T1 (hr) | Novi heterociklički derivati i njihova uporaba u liječenju neuroloških poremećaja | |
| HRP20171824T1 (hr) | (TIENO[2,3-b][1,5]BENZOKSAZEPIN-4-IL)PIPERAZIN-1-ILNI SPOJEVI S DVOJNOM AKTIVNOŠĆU INVERZNIH AGONISTA H1 I ANTAGONISTA 5-HT2A | |
| WO2014093583A3 (en) | Synthetic methods for preparing 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, other salt forms of this compound and intermediates thereof | |
| MX2015015893A (es) | 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen. | |
| HRP20140880T1 (hr) | Tekuä†a formulacija soli 1-/2-(2,4 dimetilfenilsulfanil)fenil/piperazina | |
| HRP20100516T1 (hr) | Tiazolpirazolopirimidini kao antagonisti receptora crf1 | |
| JP2004517852A5 (hr) | ||
| HRP20120867T1 (hr) | Selurampanel | |
| JP2009538867A5 (hr) | ||
| AR058151A1 (es) | Compuestos antagosnistas de los receptores 2 de dopamina de rapida disociacion | |
| HRP20130984T1 (hr) | Spoj aciltiouree ili njegove soli, i njegova primjena | |
| HRP20120748T1 (hr) | Heterocikliäśki spoj i farmaceutski sastavi koji ga sadrže | |
| HRP20120876T1 (hr) | Brzo disocirajuä†i antagonisti dopamin 2 receptora | |
| AR074204A1 (es) | Arilpiperazinas y su uso como antagonistas alfa -2c | |
| HRP20211182T1 (hr) | Dopamin d3 receptora selektivni antagonisti/djelomični agonisti; postupci izrade i njihova uporaba | |
| JP2019537592A5 (hr) |